Rifaximin (Zaxine) for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients > 18 years of age
The objective of this report was to perform a systematic review of the beneficial and harmful effects of rifaximin for reducing the risk of overt hepatic encephalopathy (HE) recurrence in patients > 18 years of age who are at risk of HE recurrence despite the use of lactulose, or who are intolera...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2015, 2015
|
| Series: | Common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of rifaximin for reducing the risk of overt hepatic encephalopathy (HE) recurrence in patients > 18 years of age who are at risk of HE recurrence despite the use of lactulose, or who are intolerant to lactulose |
|---|---|
| Physical Description: | 1 PDF file illustrations |